priors.science/reviews/perioperative-immunotherapy-solid-tumours

Perioperative Immunotherapy Solid Tumours

The current evidence on 17 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

17claims tracked

153primary papers reviewed

9 Aug 2026latest evidence review

Weeklyre-scored against new papers

7 Established · 7 Likely · 3 Uncertain · 0 Doubtful | four-reviewer panel · PICO Framework

ClaimStandingEvidence certaintyCorpus

KEYNOTE-522 pathological complete response and event-free survival in triple-negative breast cancerTnbcEstablished90%10

Adjuvant nivolumab vs ipilimumab in melanomaMelanomaEstablished88%13

Adjuvant pembrolizumab in stage III melanomaMelanomaEstablished88%12

Perioperative nivolumab event-free survival in non-small cell lung cancerNsclcEstablished87%14

Adjuvant nivolumab disease-free survival in bladder cancerBladderEstablished85%10

Perioperative immune checkpoint inhibitor expansion in muscle-invasive bladder cancerBladderEstablished85%10

Perioperative pembrolizumab event-free and overall survival in non-small cell lung cancerNsclcEstablished85%12

Adjuvant pembrolizumab disease-free and overall survival in renal cell carcinomaRCCLikely82%9

Microsatellite instability-high colon cancer immune checkpoint inhibitor surrogate biomarkerMsi ColonLikely78%3

Adjuvant pembrolizumab disease-free survival in non-small cell lung cancerNsclcLikely78%9

Neoadjuvant dual immune checkpoint inhibitor pathological complete response in microsatellite instability-high colon cancerMsi ColonLikely77%10

Adjuvant pembrolizumab in stage IIB-C melanomaMelanomaLikely76%16

Pathological complete response surrogate for triple-negative breast cancer immune checkpoint inhibitor therapyTnbcLikely72%7

Pathological complete response as surrogate for non-small cell lung cancer immune checkpoint inhibitor therapyNsclcLikely71%10

Adjuvant immune checkpoint inhibitor benefit is agent-specific in renal cell carcinomaRCCUncertain63%9

Adjuvant nivolumab benefit independent of PD-L1 statusBladderUncertain55%9

Immune checkpoint inhibitor neoadjuvant benefit inconsistent in triple-negative breast cancerTnbcUncertain54%11

Track Perioperative Immunotherapy Solid Tumours.

These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.

Track this topic →

Standing — what the evidence certainty means

Established≥ 85%Strong, consistent evidence. Unlikely to change.

Likely70–84%Well supported, with some gaps or indirect evidence.

Uncertain50–69%Mixed or limited evidence. Genuinely open.

Doubtful30–49%Little support; the weight of evidence leans against it.

Refuted< 30%The evidence contradicts it — confidently false as stated.